Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ID93 + GLA-SE therapeutic vaccine study in rifampicin-susceptible pulmonary tuberculosis
PACTR202603574281832Phase 2Not yet recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2026
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in Tuberculosis (TB) and pulmonary tuberculosis (TB) comparing ID93 + GLA-SE plus standard tuberculosis treatment with Placebo plus standard tuberculosis treatment (2 arms). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
ID93 + GLA-SE
03
Conditions
Tuberculosis (TB)pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on PACTR202603574281832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202603574281832.